DEUTSCHE BIOTECH INNOVATIV AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.35 EUR | 0.00% |
|
0.00% | -82.80% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2021 | - | Sales 2022 | - | Capitalization | 25.39M 27.35M |
|---|---|---|---|---|---|
| Net income 2021 | - 0 | Net income 2022 | - 0 | EV / Sales 2021 | - |
| Net cash position 2021 | 18.92K 20.39K | Net cash position 2022 | 8.08K 8.7K | EV / Sales 2022 | - |
| P/E ratio 2021 |
-371
x | P/E ratio 2022 |
-107
x | Employees | 1 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
More news
| 1 month | +29.81% | ||
| 3 months | -74.29% | ||
| 6 months | -79.55% | ||
| Current year | -82.80% |
1 week
1.35
1.35
1 month
1.001.51
Current year
0.956.00
1 year
0.9517.10
3 years
0.95102.00
5 years
0.95127.00
10 years
0.95127.00
| Managers | Title | Age | Since |
|---|---|---|---|
Bernd Wegener
CEO | Chief Executive Officer | 76 | 08-12-31 |
Metod Miklus
COO | Chief Operating Officer | 65 | 19-10-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernd Wegener
CEO | Chief Executive Officer | 76 | 08-12-31 |
Metod Miklus
COO | Chief Operating Officer | 65 | 19-10-06 |
Renke Lührs
CHM | Chairman | 64 | 11-02-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 1.35 | 0.00% | 6 |
| 24-05-02 | 1.35 | 0.00% | 6 |
| 24-04-30 | 1.35 | 0.00% | 6 |
| 24-04-29 | 1.35 | 0.00% | 6 |
End-of-day quote BOERSE DUESSELDORF, May 02, 2024
More quotes
Deutsche Biotech Innovativ AG, formerly, Venetus Beteiligungen AG, is a Germany-based biotechnology company. The Company focuses on the identification of relevant biomarkers in the blood of affected patients and develops targeted therapies to prevent septic shock and inhibit tumour growth, as well as a small molecule drug for breast cancer prevention, Procizumab, focus on antibody-based therapy for the treatment of organ failure in patients with cardiogenic shock. Its product portfolio comprises various indicators, among others, for sepsis therapy (Adrecizumab), for breast cancer prevention (DB1RA) and for cancer therapy (AB2302). Its research and development activities are entirely conducted by project companies, in which the Company holds interest.
| 1st Jan change | Capi. | |
|---|---|---|
| -82.80% | 1.38M | |
| +20.79% | 47.9B | |
| +46.56% | 41.42B | |
| -2.61% | 40.7B | |
| -6.20% | 28.92B | |
| +10.21% | 25.55B | |
| -21.83% | 19.27B | |
| -2.00% | 12.15B | |
| +30.77% | 12.14B | |
| -0.82% | 11.99B |
- Stock Market
- Equities
- DBI Stock